Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

EHA 2016 | How to manage myelofibrosis patients on momelotinib who develop peripheral neuropathy

Haifa Kathrin Al-Ali • 10 Jun 2016

EHA 2016

Myelofibrosis Momelotinib

Haifa Kathrin Al-Ali, MD from the University of Leipzig, Leipzig, Germany discusses what can be done for myelofibrosis patients who develop peripheral neuropathy while treated with momelotinib. Dr Al-Ali explains that not much can be done for those patients at the moment. If patients have diabetes, vitamin deficiencies, or other causes of peripheral neuropathy, these should be attended to. Dr Al-Ali mentions that there does not seem to be a correlation between a factor known to cause peripheral neuropathy and momelotinib. Therefore, this seems to be a drug dependent issue. Dr Al-Ali concludes that further investigation needs to be done. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

Unmet needs in polycythemia vera: improving symptoms & qualify of life

Haifa Kathrin Al-Ali • 11 Jun 2023

Pelabresib in myelofibrosis: the MANIFEST trials

Haifa Kathrin Al-Ali • 11 Jun 2023

Phase I/II study of a novel BET inhibitor, BMS-986158, alone & with ruxolitinib or fedratinib in MF

Haifa Kathrin Al-Ali • 11 Jun 2023

KRT‑232: first-in-class MDM2I for myelofibrosis R/R to JAK inhibitor therapy

Haifa Kathrin Al-Ali • 19 Jun 2020

Related Videos

JAK inhibitor combination therapy for the treatment of myelofibrosis

Ruben Mesa • 9 Dec 2023

XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF

John Mascarenhas • 10 Dec 2023

Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis

John Mascarenhas • 10 Dec 2023

Real-world analysis of the MOST study: factors impacting progression to MF in patients with ET

Ruben Mesa • 9 Dec 2023